Testing a Novel Drug for Inhibiting Oral Cancer in Cats
Feline oral squamous cell carcinoma is a devastating and painful cancer. There are few available treatments, and there is no cure. Affected cats usually do not live more than six months. Researchers will investigate a novel therapeutic approach incorporating dasatinib, a small-molecule tyrosine kinase inhibitor, into treatment. Dasatinib has shown promise in treating oral squamous cell carcinoma in humans, and this research focuses on the drug’s potential as a novel therapy for treating this disease in cats.
Principal Investigator: Dr. Stuart C. Helfand, Oregon State University
Sponsors: Anonymous, The Petco Foundation
Study ID: D14FE-015